Alirocumab and Plaque Burden In Familial Hypercholesterolaemia

Inclusion Criteria: * Have voluntarily granted informed consent (preferably in writing or, failing that, orally before independent witnesses of the research team) before carrying out the specific procedures of the trial. * Patients of both sexes aged between 35 and 65 years. * Patients with a molecular diagnosis of heterozygous HF included in the Spanish SAFEHEART registry (http://safeheart.colesterolfamiliar.org/). * Asymptomatic patients. * Patients without a previous history of clinical cardiovascular events (acute myocardial infarction \[AMI\], stroke, coronary revascularization, etc.). * Patients on optimized and stable treatment with maximum tolerated doses of a statin with or without other lipid-lowering therapies, for at least 3 months, with inadequate control, defined by a LDL-C level\> 100 mg / dL. * Availability of a coronary CTA performed in the 3 months prior to the baseline visit. If a coronary CTA is not available, this test will be performed during the selection period. * ATC of at least 64 cuts performed in a center with sufficient experience (more than 100 ACTs per year). * Patients with a PVA\> 30% in the baseline coronary CTA, performed in the last 3 months before the baseline visit. * Patients in whom treatment with alirocumab 150 mg / mL is indicated, according to the characteristics of the patient and the Praluent® technical data sheet. Exclusion Criteria: * Class\> II heart failure according to the functional classification of the NYHA scale (New Yo…